Fennec Pharmaceuticals Inc (FRX) – Strategy, SWOT and Corporate Finance Report

Fennec Pharmaceuticals Inc (FRX) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Fennec Pharmaceuticals Inc (Fennec) formerly Adherex Technologies Inc, develops drugs for cancer treatments. The company lead product candidate, Pedmark, anhydrous injection in two Phase III clinical trials for the prevention of cisplatin-induced hearing loss and ototoxicity in children. The company has licensing agreements with Oregon Health & Science University for development of its drug candidates. Fennec is headquartered in Durham, North Carolina, the US.

Scope

• Detailed information on Fennec Pharmaceuticals Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Fennec Pharmaceuticals Inc in the form of a SWOT analysis

• An in-depth view of the business model of Fennec Pharmaceuticals Inc including a breakdown and examination of key business segments

• News about Fennec Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Fennec Pharmaceuticals Inc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Fennec Pharmaceuticals Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Fennec Pharmaceuticals Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Taiho Pharmaceutical Co Ltd

Otonomy Inc

Novartis AG

Merck KGaA

Eisai Corp

Astrazeneca International

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Fennec Pharmaceuticals Inc - Key Facts

Fennec Pharmaceuticals Inc - Key Employees

Fennec Pharmaceuticals Inc - Key Employee Biographies

Fennec Pharmaceuticals Inc - Major Products and Services

Fennec Pharmaceuticals Inc - History

Fennec Pharmaceuticals Inc - Company Statement

Fennec Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Fennec Pharmaceuticals Inc - Business Description

Fennec Pharmaceuticals Inc - Corporate Strategy

Fennec Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Fennec Pharmaceuticals Inc - Strengths

Fennec Pharmaceuticals Inc - Weaknesses

Fennec Pharmaceuticals Inc - Opportunities

Fennec Pharmaceuticals Inc - Threats

Fennec Pharmaceuticals Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Mar 30, 2021: Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

Nov 16, 2020: Fennec Pharmaceuticals announces third quarter 2020 financial results and provides business update

Aug 12, 2020: Fennec Pharmaceuticals to participate in upcoming investor conferences

Aug 05, 2020: Fennec Pharmaceuticals announces second quarter 2020 financial results and provides business update

May 14, 2020: Fennec Pharmaceuticals announces first quarter 2020 financial results and provides business update

Feb 14, 2020: Fennec provides business update and announces fiscal year 2019 financial results

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Fennec Pharmaceuticals Inc, Key Facts

Fennec Pharmaceuticals Inc, Key Employees

Fennec Pharmaceuticals Inc, Key Employee Biographies

Fennec Pharmaceuticals Inc, Major Products and Services

Fennec Pharmaceuticals Inc, History

Fennec Pharmaceuticals Inc, Subsidiaries

Fennec Pharmaceuticals Inc, Key Competitors

Fennec Pharmaceuticals Inc, Ratios based on current share price

Fennec Pharmaceuticals Inc, Annual Ratios

Fennec Pharmaceuticals Inc, Annual Ratios (Cont…1)

Fennec Pharmaceuticals Inc, Interim Ratios

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Fennec Pharmaceuticals Inc, Performance Chart (2016 – 2020)

Fennec Pharmaceuticals Inc, Ratio Charts

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2745

Saved reports